source
- FDA unveils transparency roadmap with plans for public NDA/BLA disclosures and inspection report publishingThe FDA published a transparency roadmap that outlines its FY 2026 achievements and sets out priorities for FY 2027. One key priority is a proposal to require public disclosure of new drug applica…
- Rare disease biotech firms expand teams as FDA approvals boost pipelinesSeveral biotech companies focused on rare diseases are actively hiring, offering opportunities for professionals interested in this niche therapeutic area. The article highlights four firms that ar…